Prodromal Interventions for Schizophrenia Vulnerability: the Risks of Being "at Risk"

Overview

Journal Schizophr Res

Specialty Psychiatry

Date 2005 Jan 18

PMID 15653260

Citations 54

Authors

Cheryl Corcoran

Dolores Malaspina

Laura Hercher

Affiliations

Soon will be listed here.

Abstract

Given the morbidity and difficulty of treating psychotic disorders, including schizophrenia, there has been a move toward identifying and treating adolescents and young adults who appear to be clinically at risk or "prodromal" to psychosis. The field now has greater specificity in identification, with rates of 40-50% conversion to frank psychosis within 1-2 years. There is further evidence that medications and other treatments may have some efficacy for "prodromal" patients, though with variable side effects. However, controversy remains about some of the inherent risks in prodromal research, such as medication exposure and stigma among false-positives. In this paper, we add to this discussion through an analysis of ethics in prodromal research from the more established field of predictive genetic testing. Issues are raised about the effects of information on patients, families, and institutions, as well as future insurability, the limits of confidentiality (as it relies on discretion of patients and families), the autonomy of minors with psychiatric symptoms, and even the risks for the true-positive patient.

Citing Articles

Ethical challenges in contemporary psychiatry: an overview and an appraisal of possible strategies and research needs.

Galderisi S, Appelbaum P, Gill N, Gooding P, Herrman H, Melillo A World Psychiatry. 2024; 23(3):364-386.

PMID: 39279422 PMC: 11403198. DOI: 10.1002/wps.21230.

Ethics of early detection of disease risk factors: A scoping review.

Jansen S, Kamphorst B, Mulder B, van Kamp I, Boekhold S, van den Hazel P BMC Med Ethics. 2024; 25(1):25.

PMID: 38443930 PMC: 10913641. DOI: 10.1186/s12910-024-01012-4.

Transdiagnostic risk of mental disorders in offspring of affected parents: a meta-analysis of family high-risk and registry studies.

Uher R, Pavlova B, Radua J, Provenzani U, Najafi S, Fortea L World Psychiatry. 2023; 22(3):433-448.

PMID: 37713573 PMC: 10503921. DOI: 10.1002/wps.21147.

How do experts in psychiatric genetics view the clinical utility of polygenic risk scores for schizophrenia?.

Moorthy T, Nguyen H, Chen Y, Austin J, Smoller J, Hercher L Am J Med Genet B Neuropsychiatr Genet. 2023; 192(7-8):161-170.

PMID: 37158703 PMC: 10524148. DOI: 10.1002/ajmg.b.32939.

Ethical Implications of the Use of Language Analysis Technologies for the Diagnosis and Prediction of Psychiatric Disorders.

Loch A, Lopes-Rocha A, Ara A, Gondim J, Cecchi G, Corcoran C JMIR Ment Health. 2022; 9(11):e41014.

PMID: 36318266 PMC: 9667377. DOI: 10.2196/41014.

References

McGorry P, Yung A, Phillips L, Yuen H, Francey S, Cosgrave E . Randomized controlled trial of interventions designed to reduce the risk of progression to first-episode psychosis in a clinical sample with subthreshold symptoms. Arch Gen Psychiatry. 2002; 59(10):921-8. DOI: 10.1001/archpsyc.59.10.921. View

Zito J, Safer D, dosReis S, Gardner J, Magder L, Soeken K . Psychotropic practice patterns for youth: a 10-year perspective. Arch Pediatr Adolesc Med. 2003; 157(1):17-25. DOI: 10.1001/archpedi.157.1.17. View

Harrigan S, McGorry P, Krstev H . Does treatment delay in first-episode psychosis really matter?. Psychol Med. 2003; 33(1):97-110. DOI: 10.1017/s003329170200675x. View

Findling R, McNamara N, Youngstrom E, Branicky L, Demeter C, Schulz S . A prospective, open-label trial of olanzapine in adolescents with schizophrenia. J Am Acad Child Adolesc Psychiatry. 2003; 42(2):170-5. DOI: 10.1097/00004583-200302000-00010. View

Pantelis C, Velakoulis D, McGorry P, Wood S, Suckling J, Phillips L . Neuroanatomical abnormalities before and after onset of psychosis: a cross-sectional and longitudinal MRI comparison. Lancet. 2003; 361(9354):281-8. DOI: 10.1016/S0140-6736(03)12323-9. View

Scahill L, Leckman J, Schultz R, Katsovich L, Peterson B . A placebo-controlled trial of risperidone in Tourette syndrome. Neurology. 2003; 60(7):1130-5. DOI: 10.1212/01.wnl.0000055434.39968.67. View

Koenigsberg H, Reynolds D, Goodman M, New A, Mitropoulou V, Trestman R . Risperidone in the treatment of schizotypal personality disorder. J Clin Psychiatry. 2003; 64(6):628-34. DOI: 10.4088/jcp.v64n0602. View

Brewer W, Wood S, McGorry P, Francey S, Phillips L, Yung A . Impairment of olfactory identification ability in individuals at ultra-high risk for psychosis who later develop schizophrenia. Am J Psychiatry. 2003; 160(10):1790-4. DOI: 10.1176/appi.ajp.160.10.1790. View

Wood S, Pantelis C, Proffitt T, Phillips L, Stuart G, Buchanan J . Spatial working memory ability is a marker of risk-for-psychosis. Psychol Med. 2003; 33(7):1239-47. DOI: 10.1017/s0033291703008067. View

10.

Masi G, Cosenza A, Mucci M, Brovedani P . A 3-year naturalistic study of 53 preschool children with pervasive developmental disorders treated with risperidone. J Clin Psychiatry. 2003; 64(9):1039-47. DOI: 10.4088/jcp.v64n0909. View

11.

Zalsman G, Carmon E, Martin A, Bensason D, Weizman A, Tyano S . Effectiveness, safety, and tolerability of risperidone in adolescents with schizophrenia: an open-label study. J Child Adolesc Psychopharmacol. 2003; 13(3):319-27. DOI: 10.1089/104454603322572651. View

12.

Gilbert D, Batterson J, Sethuraman G, Sallee F . Tic reduction with risperidone versus pimozide in a randomized, double-blind, crossover trial. J Am Acad Child Adolesc Psychiatry. 2004; 43(2):206-14. DOI: 10.1097/00004583-200402000-00017. View

13.

Melle I, Larsen T, Haahr U, Friis S, Johannessen J, Opjordsmoen S . Reducing the duration of untreated first-episode psychosis: effects on clinical presentation. Arch Gen Psychiatry. 2004; 61(2):143-50. DOI: 10.1001/archpsyc.61.2.143. View

14.

Addington J, Van Mastrigt S, Addington D . Duration of untreated psychosis: impact on 2-year outcome. Psychol Med. 2004; 34(2):277-84. DOI: 10.1017/s0033291703001156. View

15.

Yung A, Phillips L, Yuen H, McGorry P . Risk factors for psychosis in an ultra high-risk group: psychopathology and clinical features. Schizophr Res. 2004; 67(2-3):131-42. DOI: 10.1016/S0920-9964(03)00192-0. View

16.

Miller T, McGlashan T, Rosen J, Cadenhead K, Cannon T, Ventura J . Prodromal assessment with the structured interview for prodromal syndromes and the scale of prodromal symptoms: predictive validity, interrater reliability, and training to reliability. Schizophr Bull. 2004; 29(4):703-15. DOI: 10.1093/oxfordjournals.schbul.a007040. View

17.

Lencz T, Smith C, Auther A, Correll C, Cornblatt B . The assessment of "prodromal schizophrenia": unresolved issues and future directions. Schizophr Bull. 2004; 29(4):717-28. DOI: 10.1093/oxfordjournals.schbul.a007041. View

18.

Johnstone E, Crow T, Johnson A, Macmillan J . The Northwick Park Study of first episodes of schizophrenia. I. Presentation of the illness and problems relating to admission. Br J Psychiatry. 1986; 148:115-20. DOI: 10.1192/bjp.148.2.115. View

19.

Loebel A, Lieberman J, Alvir J, Mayerhoff D, Geisler S, Szymanski S . Duration of psychosis and outcome in first-episode schizophrenia. Am J Psychiatry. 1992; 149(9):1183-8. DOI: 10.1176/ajp.149.9.1183. View

20.

Ford D, Easton D, Bishop D, Narod S, Goldgar D . Risks of cancer in BRCA1-mutation carriers. Breast Cancer Linkage Consortium. Lancet. 1994; 343(8899):692-5. DOI: 10.1016/s0140-6736(94)91578-4. View